Optimum β-adrenolytic drug in ischaemic heart disease – why is it worth choosing bisoprolol?

Marcin Barylski

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

1/2018
vol. 4

Send email

Copy url:

abstract:

Review paper

Optimum β-adrenolytic drug in ischaemic heart disease – why is it worth choosing bisoprolol?

Marcin Barylski

Online publish date: 2018/03/12

View full text Get citation

Bisoprolol is one of the group of modern β-adrenolytics without vasodilator properties, being also a highly cardioselective drug. In contrast to third-generation β-adrenolytics (nebivolol, carvedilol), bisoprolol much more effectively and quickly reduces heart rate, so we should use it when we want more effective control of heart rate, which is extremely important in patients with ischaemic heart disease.

keywords:

Optimum β-adrenolytic drug in ischaemic heart disease – why is it worth choosing bisoprolol?

Marcin Barylski

β-adrenolytic drug, bisoprolol, ischaemic heart disease